TrialSignal
Clinical trial intelligence report
Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00397423
Status
COMPLETED
Phase
PHASE2
Sponsor
Peking University
Executive brief
Investment-Ready Snapshot
Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response is a PHASE2 clinical asset sponsored by Peking University in Amyotrophic Lateral Sclerosis. SEO and diligence focus: Granulocyte Colony Stimulating Factor, NS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00397423
Indication
Amyotrophic Lateral Sclerosis
Modality
small molecule
Target
Granulocyte Colony Stimulating Factor, NS
Intervention
Granulocyte Colony Stimulating Factor, NS
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.